Author： Churchill Clare A C
Publisher： Palgrave Macmillan Ltd
ISSN： 1478-565X
Source： Journal of Commercial Biotechnology, Vol.12, Iss.3, 2006-04, pp. : 237-241
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strategic market analysis team has therefore analysed this market to identify key biological products, together with growth drivers and resistors shaping the growth of this market. The AIID market covers a wide range of indications; however, the most prevalent are rheumatoid arthritis and psoriasis, which together represent a significant healthcare burden. A range of monoclonal antibody therapeutics such as Abbott/CAT's Humira are set to drive AIID biological market growth, together with Amgen/Wyeth's fusion protein Enbrel. Owing to very strong sales of Enbrel as a result of continued label expansion, Amgen is set to record the greatest biological AIID sales from 2004 to 2010. Many of the highly efficacious AIID biologicals such as Enbrel target TNF, which is rapidly emerging as the leading cytokine target for many AIID indications. Overall, AIID biologicals generated US5.4bn in 2004, and this is set to rise to US14.3bn by 2010: a strong compound annual growth rate of 17.9 per cent.Journal of Commercial Biotechnology (2006) 12, 237–241; doi:10.1057/palgrave.jcb.3040172
Related content
Access to resources
Recommend
Key financial trends that shape biotech business growth
Journal of Commercial Biotechnology, Vol. 11, Iss. 2, 2005-01 ,pp. :
Journal of Commercial Biotechnology, Vol. 11, Iss. 3, 2005-04 ,pp. :